Disorders of the Nervous System

Neuronal Correlates of Hyperalgesia and Somatic Signs of Heroin Withdrawal in Male and Female Mice

Yocasta Alvarez-Bagnarol,1,2,3 Renata C. N. Marchette,2 Chase Francis,1 Marisela Morales,1 and Leandro F. Vendruscolo2

https://doi.org/10.1523/ENEURO.0106-22.2022

1Neuronal Networks Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224, 2Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224, and 3Department of Anatomy and Neurobiology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico 00936-5067

Abstract

Opioid withdrawal involves the manifestation of motivational and somatic symptoms. However, the brain structures that are involved in the expression of different opioid withdrawal signs remain unclear. We induced opioid dependence by repeatedly injecting escalating heroin doses in male and female C57BL/6J mice. We assessed hyperalgesia during spontaneous heroin withdrawal and somatic signs of withdrawal that was precipitated by the preferential μ-opioid receptor antagonist naloxone. Heroin-treated mice exhibited significantly higher hyperalgesia and somatic signs than saline-treated mice. Following behavioral assessment, we measured regional changes in brain activity by automated the counting of c-Fos expression (a marker of cellular activity). Using Principal Component Analysis, we determined the association between behavior (hyperalgesia and somatic signs of withdrawal) and c-Fos expression in different brain regions. Hyperalgesia was associated with c-Fos expression in the lateral hypothalamus, central nucleus of the amygdala, ventral tegmental area, parabrachial nucleus, dorsal raphe (DR), and locus coeruleus (LC). Somatic withdrawal was associated with c-Fos expression in the paraventricular nucleus of the thalamus, lateral habenula, DR, and LC. Thus, hyperalgesia and somatic withdrawal signs were each associated with c-Fos expression in unique sets of brain areas. The expression of c-Fos in the DR and LC was associated with both hyperalgesia and somatic withdrawal. Understanding common neurobiological mechanisms of acute and protracted opioid withdrawal may help identify new targets for treating this salient aspect of opioid use disorder.

Key words: neuronal activity; opioids; pain; reinforcement; reward; stress

Significance Statement

The public impact of the opioid crisis has prompted an effort to understand the neurobiological mechanisms of opioid use disorder (OUD). The need to avoid withdrawal symptoms is hypothesized to drive compulsive drug-taking and drug-seeking in OUD. Thus, understanding the mechanisms of acute and protracted opioid withdrawal may help identify new targets for treating this salient aspect of OUD. We reported brain structures that are associated with the expression of hyperalgesia and somatic signs of opioid withdrawal in male and female heroin-dependent mice. Hyperalgesia during spontaneous opioid withdrawal and somatic withdrawal resulted in c-Fos expression in autonomic and limbic brain regions. The expression of c-Fos in the dorsal raphe (DR) and locus coeruleus (LC) were associated with both hyperalgesia and somatic withdrawal.
Introduction

Opioid use disorder (OUD) is a global burden with the highest estimated prevalence observed in the United States (GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017). The high prevalence of OUD has contributed to a national crisis. Nearly 92,000 individuals died from an opioid overdose in 2020 (National Institute on Drug Abuse, 2022). The public impact of the opioid crisis has prompted a national effort to understand the underlying neurobiological mechanisms of OUD. Opioid withdrawal is a physically and emotionally painful state that is hypothesized to drive continued drug taking and seeking and promote relapse in individuals with OUD. Opioid withdrawal signs include somatic and motivational signs, such as diarrhea, insomnia, fever, pain, anxiety, and depression (Koob, 2020, 2021). Somatic withdrawal varies in severity and duration, but it usually resolves within days or weeks, whereas motivational signs of withdrawal, such as heightened pain sensitivity (i.e., hyperalgesia), can persist for months or even years after the discontinuation of opioid use (Shurman et al., 2010; Carcoba et al., 2011).

Neuroimaging studies provide evidence of functional changes in brain regions during opioid withdrawal. Functional magnetic resonance imaging (fMRI) studies demonstrate that male OUD patients exhibit higher blood oxygen level-dependent (BOLD) signals in several brain regions, including the nucleus accumbens (NAc), caudate putamen, amygdala, hippocampus, prefrontal cortex (PFC), orbitofrontal cortex (OFC), medial frontal gyrus, thalamus, cingulate cortex, and subcallosal gyrus (Li et al., 2012; Murphy et al., 2018), during acute and short-term opioid abstinence. Greater subjective opioid craving scores correlated with greater activation of the NAc, caudate, putamen, and cingulate cortex (Murphy et al., 2018). A photon emission computed tomography study identified lower blood flow in the thalamus in opioid-dependent male and female patients during naloxone-precipitated withdrawal (Krystal et al., 1995). In healthy males, naloxone administration increased neural activity in the pregenual cingulate, putamen, caudate, insula, hippocampus, and entorhinal cortex (Borras et al., 2004; Chu et al., 2015). The effects of naloxone on perceived pain intensity in response to a noxious thermal stimulus indicated greater activation of the insula, OFC, thalamus, and hippocampus (Borras et al., 2004). The assessment of objective and subjective symptoms of opioid withdrawal showed that naloxone had a minimal impact on withdrawal in healthy individuals, but changes in activity in the inferior orbital frontal gyri were associated with subjective withdrawal experience (Chu et al., 2015).

Preclinical studies identified associations between the activation of several brain regions and opioid withdrawal. In male morphine-dependent rats, naloxone administration increased c-fos mRNA expression in the hippocampus, lateral septal nucleus, periaqueductal gray (PAG), ventral tegmental area (VTA), locus coeruleus (LC), caudate putamen, NAc, bed nucleus of the stria terminalis (BNST), central nucleus of the amygdala (CeA), paraventricular nucleus of the hypothalamus (PVN), and lateral hypothalamus (LH; Delfs et al., 2000; Gracy et al., 2001; Frenois et al., 2002). Male morphine-dependent rats exhibited increases in glucose metabolism during naloxone-precipitated withdrawal in the CeA, the lateral habenula (LHb), the mamillary nucleus, the lateral septal nucleus, thalamic nuclei, and the interpuduncular nucleus (Wooten et al., 1982). An fMRI study in morphine-dependent rats revealed higher BOLD activity in the retrosplenial, piriform, insular, entorhinal, cingular, visual, and auditory cortices and hippocampus (Lowe et al., 2002). Altogether, these clinical and preclinical studies provide evidence of the recruitment of several brain regions during opioid withdrawal, but they do not provide information about the potential role of these regions in specific behaviors. Moreover, results from spontaneous opioid withdrawal, which more closely mimics opioid withdrawal in humans (Azar et al., 2004; Papaleo and Contarino, 2006), are very limited.

Although sex differences in opioid dependence have been reported in humans and rodents (Zachry et al., 2019; Marchette et al., 2021; Pantazis et al., 2021), most studies were conducted in male subjects. Previous studies found that female opioid-dependent mice and rats exhibited similar levels of somatic signs of naloxone-precipitated heroin withdrawal compared with male opioid-dependent mice and rats (Cicero et al., 2002; Towers et al., 2019). A recent study reported an increase in c-Fos expression in the PAG, CeA, BNST, LHb, and paraventricular nucleus of the thalamus (PVT) following naloxone withdrawal-induced hyperalgesia in male and female oxycodone-dependent rats, but sex differences were not assessed (Simpson et al., 2020).

In the present study, we tested the hypothesis that hyperalgesia during spontaneous withdrawal and naloxone-precipitated somatic signs of withdrawal are associated with unique sets of brain region activity, but some of these regions are involved in both behavioral aspects of opioid withdrawal. We tested behavior and c-Fos expression in both male and female mice. We applied an unbiased approach to assess changes in neuronal activity throughout the brain that resulted from hyperalgesia...
during spontaneous opioid withdrawal and somatic signs that were precipitated by naloxone in male and female mice.

**Materials and Methods**

**Animals**

We used eight-week-old male and female C57BL/6J mice (The Jackson Laboratory). The mice were group-housed (three per cage) with the same sex and treatment condition (saline or heroin) in a temperature-controlled (23°C) vivarium with a 12/12 h light/dark cycle (lights on at 6:30 A.M.). We provided food and water *ad libitum* except during the experimental sessions. The study adhered to the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* and was approved by the National Institute on Drug Abuse Animal Care and Use Committee.

**Drugs**

We dissolved diamorphine hydrochloride (heroin; Research Triangle Institute), dispensed by the National Institute on Drug Abuse, Intramural Research Program Pharmacy, in sterile saline (0.9% sodium chloride; Hospira) at concentrations of 0.5–5 mg/ml. Heroin was administered subcutaneously in a volume of 10 ml/kg. We dissolved naloxone hydrochloride (DuPont Pharmaceuticals) in sterile saline at a concentration of 0.1 mg/ml. Naloxone was administered intraperitoneally in a volume of 10 ml/kg. We weighed the mice immediately before each injection with saline, heroin, or naloxone.

**Behavioral studies**

**Hyperalgesia during spontaneous heroin withdrawal**

We assessed hyperalgesia by evaluating mechanical sensitivity using an electronic von Frey device (Ugo Basile). We habituated the mice to the testing room for at least 30 min. For acclimatization, we placed the mice in the testing apparatus for at least 1 h and started testing when exploratory behaviors ceased. The testing apparatus consisted of an elevated platform (92 cm in length × 28 cm in width × 71 cm in height) with a stainless-steel mesh floor (0.4 × 0.4 cm) and rectangular transparent compartments (10 × 10 × 13 cm) on top. For baseline measurements, we assessed mechanical sensitivity by applying a single unbending filament perpendicularly to the mid-plantar surface of either the left or right hind paw. The force at which the mouse retracted its paw in response to the stimulation [i.e., paw withdrawal threshold in gram-force (gf)] was recorded automatically by the von Frey device. We continued measuring the withdrawal threshold of the mice in adjacent boxes until we assessed withdrawal thresholds of each mouse at least once. We then repeated the process five times, alternating between the left and right hind paws until a total of six measurements for each mouse (three per paw) were collected. We calculated the average of the six measurements of paw withdrawal thresholds of each mouse and considered it as a measure of mechanical sensitivity.

After obtaining baseline measurements, we randomly assigned the mice to the experimental groups. One group received injections of saline (10 ml/kg, s.c.), and the other groups received increasing doses of heroin (5, 10, 20, and 40 mg/kg, s.c.) twice daily (7 A.M. and 7 P.M.) for four consecutive days. Around 16 h after the last saline or heroin injection, we assessed paw withdrawal thresholds by von Frey testing as described above (Fig. 1A). To correlate behavior and c-Fos expression, we obtained a single numeric value that was representative of hyperalgesia by calculating the change (Δ) in paw withdrawal thresholds for each mouse. We obtained the Δ of paw withdrawal thresholds by subtracting paw withdrawal thresholds during withdrawal from paw withdrawal thresholds during baseline.

As an index of general opioid effects, we weighed the male and female mice daily across treatment. We calculated the total percentage of bodyweight loss by dividing the weight lost by the weight before the first injection multiplied by 100.

**Naloxone-precipitated heroin withdrawal**

We injected mice with saline (10 ml/kg, s.c.) or increasing doses of heroin (10, 20, 30, 40, and 50 mg/kg, s.c.) twice daily (7 A.M. and 7 P.M.) for five consecutive days. On the day of the test (day 6 of the experimental timeline; Fig. 2A), we treated the mice with a single injection of saline or heroin (50 mg/kg). Two hours later, we injected the mice with the preferential μ-opioid receptor antagonist naloxone (1 mg/kg, i.p.) and immediately placed them individually in transparent cages to record somatic signs of naloxone-precipitated opioid withdrawal for 20 min. We counted the number of paw tremors (i.e., “clapping” front paws), jumps, and “wet-dog” shakes. We assigned one point per observation for each behavior. We also assigned one point per observation for the appearance of less frequent signs of withdrawal, such as abnormal posture, genital grooming, and diarrhea. To correlate behavior and c-Fos expression, we obtained a single numeric value that was representative of somatic withdrawal by summing the number of occurrences of these somatic signs.

**Anatomical/histologic studies**

**Tissue preparation and c-Fos immunolabeling**

We perfused mice 1 h after the end of behavioral testing to detect the expression of c-Fos protein (Figs. 1B, 2B). We anesthetized the mice with an injection of Euthasol (pentobarbital sodium; 100 mg/kg, i.p., 3 ml/kg) and transcardially perfused them with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB). We kept the brains in 4% PFA for 2 h, then kept them in 18% sucrose solution overnight at 4°C. We collected free-floating coronal serial cryosections (16 μm thick) from the entire brain of each mouse with a cryostat (CM3050 S, Leica). To reduce c-Fos staining variability that can be caused by extraneous factors, we performed parallel immunohistological staining of a set of sections from mice of each behavioral cohort (i.e., male heroin, male saline, female heroin, and female saline).
We rinsed the cryosections with PB three times for 10 min each. We incubated the cryosections in 0.3% H2O2 for 15 min to quench endogenous peroxidase activity. Next, we rinsed and placed the sections for 1 h in blocking solution (4% bovine serum albumin and 0.3% Triton X-100 in PB). We incubated the sections overnight at 4°C with rabbit anti-phospho-c-Fos (1:2000; catalog #5348; Cell Signaling Technology) in blocking solution. After rinsing with PB three times for 10 min each, we incubated the sections for 1 h at room temperature with biotinylated goat anti-rabbit antibody (1:200; catalog #PK6101; Vector Laboratories) in blocking solution. We incubated the sections for 1 h at room temperature in avidin-biotinylated horseradish peroxidase (1:100, VECTASTAIN Elite ABC-HRP kit, Vector Laboratories). We developed the peroxidase reaction with 0.05% 3,3’-diaminobenzidine (DAB) and 0.003% H2O2, rinsed the sections with PB three times for 10 min each, and mounted the sections on gelatin-coated slides. After drying overnight at room temperature, we dehydrated the sections through a series of graded alcohols, cleared the sections with Histoclear, and cover-slipped the sections with Permount mounting medium (catalog #SP15-100; Fisher Scientific). Using an Olympus VS120 microscope (Olympus), we took brightfield images of whole sections that were magnified with a 20x objective.

**c-Fos segmentation and atlas registration**

For the automatic cell detection and counting of labeled c-Fos protein, we wrote two macros (available as Extended Data) using Image-Pro 10.0 software (Media Cybernetics). The automated macros quantified stained nuclei by extracting RGB values of the image and applying iterative morphologic segmentation. For the optimal detection of DAB staining, the macro preprocessed the images by performing spatial calibration and color extraction to view images as an eight-bit gray scale image. This allowed us to convert the original image to other color spaces to eliminate the correlation between RGB values and thus associate each image pixel to a different stain based on thresholds. We scaled the images to their representative plate in the mouse brain atlas (K consman, 2003) to select and manually draw contours of regions of interest. We focused our analysis on subcortical regions that have been shown to be involved in withdrawal and...
negative affect (Maldonado et al., 1996; Welsch et al., 2020). To reduce variability between samples, we used a constant number of sections (4–10 per mouse, depending on the brain region) for each region of interest. We used another macro to automatically define thresholds to identify c-Fos-positive nuclei by defining the range of intensity values that distinguished them from background. To properly segment positive nuclei, the macro detected different morphologic ranges of areas based on pixel values and applied a watershed auto-split procedure of selected objects to separate clusters of positive nuclei. Finally, the macro exported the total number of positive nuclei per region of interest to an Excel spreadsheet.

Statistical analysis
The number of mice (n) that were used in each group or condition is described in each figure legend. We analyzed paw withdrawal thresholds using three-way repeated-measures ANOVA, with sex and treatment (repeated heroin or saline) as between-subjects factors and time (test day) as the within-subjects factor. Because we found no significant group or time × sex interaction, we combined the male and female data and analyzed paw withdrawal thresholds using two-way ANOVA, with time and treatment as factors. We analyzed the Δ of paw withdrawal thresholds using Student’s t test. We analyzed somatic signs of withdrawal using two-way ANOVA, with sex and treatment as between-subjects factors. For opioid withdrawal scores, because we did not observe a significant sex × treatment interaction, we combined male and female data to present the main effect of treatment. We analyzed c-Fos expression after the assessment of hyperalgesia or somatic signs of withdrawal using two-way ANOVA, with sex and treatment as between-subjects factors. We present the combined data in the main manuscript and separate sex data in the Extended Data.

We conducted Principal component analysis (PCA), which standardizes and transforms data to comparable scales, with an orthogonal normalized Varimax to search for associations between c-Fos expression and the behavioral results. We retained factors with eigenvalues >1 and considered factor loadings ≥0.7 to represent variance that was explained by the factors. We used Pearson’s correlation test to analyze c-Fos expression among brain regions. We analyzed the data using Prism 9.2 software (GraphPad) or Statistica software (Statsoft).
Results

Hyperalgesia during spontaneous withdrawal after repeated heroin injections

To model opioid dependence and produce hyperalgesia during spontaneous heroin withdrawal in male and female mice, we used a 4-d schedule of repeated subcutaneous administration of escalating heroin doses (5–40 mg/kg). We measured paw withdrawal thresholds 1 d before initiating the heroin injections (baseline) and after repeated heroin injections at 16 h into withdrawal (Fig. 1A). The three-way ANOVA (sex × treatment × time) showed significant effects of treatment ($F_{(1,52)} = 149.9$, $p < 0.0001$) and time ($F_{(1,52)} = 312.6$, $p < 0.0001$), a significant treatment × time interaction ($F_{(1,52)} = 288.2$, $p < 0.0001$), no effect of sex ($F_{(1,52)} = 0.04084$, $p = 0.8406$), no sex × treatment interaction ($F_{(1,52)} = 2.516$, $p = 0.1188$), and no sex × treatment × time interaction ($F_{(1,52)} = 2.610$, $p = 0.1122$; Fig. 1C). Because we did not observe significant interactions with the sex factor, we combined the male and female data. The two-way ANOVA (treatment × test day) showed significant effects of treatment ($F_{(1,53)} = 215.5$, $p < 0.0001$) and test day ($F_{(1,53)} = 268.9$, $p < 0.0001$) on paw withdrawal thresholds and a significant treatment × test day interaction ($F_{(1,53)} = 252.5$, $p < 0.0001$; Fig. 1D). Post hoc comparisons indicated that heroin-treated mice had significantly lower paw withdrawal thresholds compared with saline-treated mice ($p < 0.0001$) and compared with paw withdrawal thresholds during baseline ($p < 0.0001$). Student’s $t$ test of the Δ of paw withdrawal thresholds indicated that heroin-treated mice exhibited significantly higher mechanical sensitivity compared with saline-treated mice ($t_{(53)} = 16.78$, $p < 0.0001$; Fig. 1E).

We measured bodyweight in mice that were subsequently used to detect c-Fos expression after the assessment of hyperalgesia. Student’s $t$ test showed that heroin-treated mice weighed significantly less than saline-treated mice ($t_{(22)} = 10.13$, $p < 0.0001$; Extended Data Fig. 1–1).

Naloxone-precipitated somatic signs of withdrawal after repeated heroin injections

To test somatic signs of heroin withdrawal, we used a 5-d schedule of intermittent injections of escalating heroin doses (10–50 mg/kg, s.c.) and precipitated withdrawal by a single intraperitoneal injection of naloxone (1 mg/kg; Fig. 2A) 2 h after a heroin injection. Somatic signs of heroin withdrawal were assessed by counting the number of jumps, paw tremors (“clapping” of forepaws), shakes (“wet-dog” shakes), and other miscellaneous behaviors. The two-way ANOVA showed a significant treatment effect on paw tremors ($F_{(1,49)} = 23.58$, $p < 0.0001$; heroin > saline), regardless of sex (sex effect: $F_{(1,49)} = 0.236$, $p = 0.6012$; sex × treatment interaction: $F_{(1,49)} = 0.1053$, $p = 0.7473$; Fig. 2C). The two-way ANOVA also showed a significant treatment effect on wet-dog shakes ($F_{(1,49)} = 10.75$, $p = 0.0022$; heroin > saline), regardless of sex (sex effect: $F_{(1,49)} = 1.195$, $p = 0.2809$; sex × treatment interaction: $F_{(1,40)} = 0.01720$, $p = 0.8963$). The ANOVA showed significant effects of treatment ($F_{(1,40)} = 196.6$, $p < 0.0001$; heroin > saline) and sex ($F_{(1,40)} = 27.97$, $p < 0.0001$) on the number of jumps and a significant sex × treatment interaction ($F_{(1,40)} = 27.07$, $p < 0.0001$). Post hoc comparisons indicated that female heroin-treated mice exhibited a higher number of jumps compared with male heroin-treated mice ($p < 0.0001$).

The two-way ANOVA revealed that heroin-treated mice had a significantly higher opioid withdrawal score compared with saline-treated mice (treatment effect: $F_{(1,40)} = 62.10$, $p < 0.0001$), regardless of sex (sex effect: $F_{(1,40)} = 2.685$, $p = 0.1092$; sex × treatment interaction: $F_{(1,40)} = 1.62$, $p = 0.2129$; Fig. 2D). Because we did not observe a significant sex × treatment interaction, we combined male and female data to present the main effect of treatment (Fig. 2E). These results suggest that naloxone precipitated somatic withdrawal in heroin-treated mice independently of sex.

We measured bodyweight in mice that were subsequently used to detect c-Fos expression after the assessment of somatic signs of withdrawal. Student’s $t$ test showed that heroin-treated mice weighed significantly less than saline-treated mice ($t_{(22)} = 8.945$, $p < 0.0001$; Extended Data Fig. 2–1).

Increase in cellular c-Fos expression in heroin-dependent mice following the assessment of hyperalgesia during spontaneous withdrawal

To investigate brain region-specific activity that is associated with hyperalgesia during spontaneous withdrawal, we quantified c-Fos expression in brains that were collected 17 h after the last heroin injection (1 h after von Frey testing; Fig. 1A,B). We compared the regional average of c-Fos expression between heroin-treated and saline-treated male and female mice (Extended Data Fig. 3–1). Statistical values are shown in Table 1. We found an increase in c-Fos expression in female mice compared with male mice in the NAc shell, PVN, LH, LHb, PAG, SUM, and VTA. The two-way ANOVAs revealed no sex × treatment interactions for any of the analyzed brain regions. We found effects of treatment (heroin > saline) on c-Fos expression in the LH, CeA, LHb, VTA, dorsal raphe (DR), parabrachial nucleus (PBN), and LC (Fig. 3). These results indicated that spontaneous heroin withdrawal significantly increased c-Fos expression in distinct brain regions in a sex-independent manner.

We also found that the average number of c-Fos-expressing cells was significantly lower in the heroin-treated group in the PVN. We did not find significant treatment effects on c-Fos expression in the NAc shell, BNST, PVT, PAG, or supramammillary nucleus (SUM).

Increase in cellular c-Fos expression in heroin-dependent mice following the assessment of naloxone-precipitated somatic signs of opioid withdrawal

To investigate brain region-specific activity that is associated with naloxone-precipitated withdrawal, we quantified c-Fos expression in brains that were collected 3 h after the
last heroin injection (1 h after the naloxone injection; Fig. 2A, B). Statistical values are shown in Table 2. We found an increase in c-Fos expression in female mice compared with male mice in the PVT, LHb, DR, and LC and a decrease in c-Fos expression in female mice compared with male mice in the NAc shell, BNST, CeA, and PBN. The two-way ANOVAs for each brain region showed a significant sex × treatment interaction only for the SUM, but the post hoc comparisons did not reveal significant differences (Extended Data Fig. 4-1). The ANOVA detected significant effects of treatment (heroin > saline) on c-Fos expression in the NAc shell, BNST, PVN, PVT, LH, CeA, LHb, SUM, VTA, DR, PBN, and LC. No significant effects of treatment were found on c-Fos expression in the PAG (Fig. 4). These results indicated that naloxone-precipitated heroin withdrawal significantly increased c-Fos expression in distinct brain regions in a sex-independent manner.

PCA of c-Fos expression and hyperalgesia during spontaneous withdrawal

To determine the relationship between neuronal activity and hyperalgesia during spontaneous heroin withdrawal, we performed PCA to reduce dimensionality of the data from heroin-treated mice. The PCA with an orthogonal normalized varimax rotation included the average number of c-Fos-expressing neurons of each brain region and hyperalgesia during spontaneous withdrawal. The PCA of c-Fos expression and hyperalgesia during withdrawal showed a significant sex × treatment interaction for each brain region. The PCA results revealed that heroin-treated male mice had a significantly higher number of c-Fos-expressing neurons in the NAc shell, BNST, PVN, PVT, LH, and LC compared with saline-treated male mice. In contrast, heroin-treated female mice had a significantly lower number of c-Fos-expressing neurons in the NAc shell, BNST, PVN, PVT, LH, and LC compared with saline-treated female mice. The PCA results also showed that heroin-treated male mice had a significantly higher paw withdrawal threshold than saline-treated male mice. In contrast, heroin-treated female mice had a significantly lower paw withdrawal threshold than saline-treated female mice. The PCA results indicated that heroin withdrawal significantly increased c-Fos expression and decreased paw withdrawal thresholds in male and female mice.

Table 1: Two-way ANOVA results of Fos quantification in analyzed brain regions following hyperalgesia during spontaneous withdrawal

| Brain region | Treatment effect | Sex effect | Sex × treatment interaction |
|--------------|-----------------|------------|----------------------------|
| NAc shell | $F_{(1,19)} = 0.8349, p = 0.3723$ | $F_{(1,19)} = 10.41, p = 0.0044; F > M$ | $F_{(1,19)} = 0.05892, p = 0.8108$ |
| BNST | $F_{(1,19)} = 1.926, p = 0.1813$ | $F_{(1,19)} = 4.275, p = 0.0526$ | $F_{(1,19)} = 0.4395, p = 0.6153$ |
| PVN | $F_{(1,19)} = 30.16, p < 0.0001$ | $F_{(1,19)} = 8.964, p = 0.0075; F > M$ | $F_{(1,19)} = 0.2445, p = 0.6344$ |
| PVT | $F_{(1,19)} = 0.1164, p = 0.7367$ | $F_{(1,19)} = 2.544, p = 0.1272$ | $F_{(1,19)} = 0.2627, p = 0.6142$ |
| LH | $F_{(1,19)} = 16.93, p < 0.001$ | $F_{(1,19)} = 5.546, p = 0.0294; F > M$ | $F_{(1,19)} = 0.1327, p = 0.7197$ |
| CeA | $F_{(1,19)} = 26.37, p < 0.0001$ | $F_{(1,19)} = 1.876, p = 0.1867$ | $F_{(1,19)} = 0.09373, p = 0.7628$ |
| LHb | $F_{(1,19)} = 40.80, p < 0.0001$ | $F_{(1,19)} = 8.195, p = 0.0100; F > M$ | $F_{(1,19)} = 0.9071, p = 0.3528$ |
| PAG | $F_{(1,19)} = 1.136, p = 0.2998$ | $F_{(1,19)} = 8.589, p = 0.0086; F > M$ | $F_{(1,19)} = 0.005, p = 0.9441$ |
| SUM | $F_{(1,19)} = 4.195, p = 0.0546$ | $F_{(1,19)} = 14.44, p = 0.0012; F > M$ | $F_{(1,19)} = 0.007174, p = 0.9334$ |
| VTA | $F_{(1,19)} = 27.39, p < 0.0001$ | $F_{(1,19)} = 5.773, p = 0.0267; F > M$ | $F_{(1,19)} = 0.1231, p = 0.2810$ |
| DR | $F_{(1,19)} = 11.70, p < 0.0001$ | $F_{(1,19)} = 1.803, p = 0.1952$ | $F_{(1,19)} = 0.08641, p = 0.3642$ |
| PBN | $F_{(1,19)} = 46.15, p < 0.0001$ | $F_{(1,19)} = 0.2822, p = 0.6014$ | $F_{(1,19)} = 0.1759, p = 0.6796$ |
| LC | $F_{(1,19)} = 17.91, p < 0.0001$ | $F_{(1,19)} = 0.5460, p = 0.4695$ | $F_{(1,19)} = 0.5909, p = 0.4520$ |

Males (M), Females (F).
treated mice (Fig. 5A). The analysis showed two factors that together accounted for >70% of the data variance. Factor 1 accounted for 53.54% of the variance, whereas factor 2 accounted for 20.51% of the variance. Hyperalgesia and c-Fos expression in the DR, LC, CeA, VTA, LH, and PBN loaded onto the first principal component (PC1). The second principal component (PC2) included c-Fos expression in the BNST, PVT, LHb, NAc shell, SUM, and PAG. Because these factors were orthogonal to each other, we considered them independent from each other and inferred that brain regions that loaded onto PC1 may be functionally involved in hyperalgesia, whereas brain regions that loaded onto PC2 may be involved in spontaneous withdrawal signs other than hyperalgesia. Bodyweight loss and the PVN did not load onto PC1 or PC2.

### Table 2: Two-way ANOVA results of Fos quantification in analyzed brain regions following naloxone-precipitated somatic signs of opioid withdrawal

| Brain region | Treatment effect | Sex effect | Sex × treatment interaction |
|--------------|------------------|------------|-----------------------------|
| NAc shell    | \( F_{1,18} = 15.91, p < 0.001 \) | \( F_{1,18} = 40.50, p < 0.0001; M > F \) | \( F_{1,18} = 1.781, p = 0.1986 \) |
| BNST         | \( F_{1,18} = 29.53, p < 0.0001 \) | \( F_{1,18} = 14.97, p = 0.0011; M > F \) | \( F_{1,18} = 1.470, p = 0.2411 \) |
| PVN          | \( F_{1,18} = 43.11, p < 0.0001 \) | \( F_{1,18} = 1.915, p = 0.1833 \) | \( F_{1,18} = 0.1469, p = 0.7060 \) |
| PVT          | \( F_{1,18} = 5.069, p < 0.05 \)  | \( F_{1,18} = 4.738, p = 0.0431; F > M \) | \( F_{1,18} = 1.023, p = 0.3253 \) |
| LH           | \( F_{1,18} = 30.28, p < 0.001 \) | \( F_{1,18} = 0.3534, p = 0.5436 \) | \( F_{1,18} = 0.04941, p = 0.8266 \) |
| CeA          | \( F_{1,18} = 17.40, p < 0.001 \) | \( F_{1,18} = 23.89, p = 0.0001; M > F \) | \( F_{1,18} = 3.703, p = 0.0703 \) |
| LHb          | \( F_{1,18} = 18.28, p < 0.001 \) | \( F_{1,18} = 8.314, p = 0.0099; F > M \) | \( F_{1,18} = 1.297, p = 0.2697 \) |
| PAG          | \( F_{1,18} = 3.855, p = 0.0652 \) | \( F_{1,18} = 0.02565, p = 0.8746 \) | \( F_{1,18} = 0.3041, p = 0.5881 \) |
| SUM          | \( F_{1,18} = 33.96, p < 0.0001 \) | \( F_{1,18} = 1.128, p = 0.3023 \) | \( F_{1,18} = 6.029, p = 0.0245 \) |
| VTA          | \( F_{1,18} = 24.40, p < 0.0001 \) | \( F_{1,18} = 2.406, p = 0.1383 \) | \( F_{1,18} = 1.791, p = 0.1975 \) |
| DR           | \( F_{1,18} = 14.54, p < 0.01 \)  | \( F_{1,18} = 12.91, p = 0.0021; F > M \) | \( F_{1,18} = 0.116, p = 0.7422 \) |
| PBN          | \( F_{1,18} = 27.17, p < 0.0001 \) | \( F_{1,18} = 18.16, p = 0.0005; M > F \) | \( F_{1,18} = 0.1257, p = 0.7271 \) |
| LC           | \( F_{1,18} = 88.91, p < 0.0001 \) | \( F_{1,18} = 29.03, p < 0.0001; F > M \) | \( F_{1,18} = 2.218, p = 0.1537 \) |

Males (M), Females (F).

### PCA of c-Fos expression and naloxone-precipitated somatic signs of opioid withdrawal

The PCA with an orthogonal normalized varimax rotation included the average number of c-Fos-expressing neurons of each brain region and somatic opioid withdrawal scores of male and female heroin-treated mice (Fig. 5B). The analysis showed two factors that together accounted for >70% of the data variance. The PC1 accounted for 37.03% of the variance and included the LH, SUM, PBN, BNST, N Ac shell, and CeA. Somatic withdrawal and the DR, LC, LHb, and PVT loaded onto PC2 (accounting for 35.19% of the variance). From these findings, we inferred that brain regions that loaded onto PC2 may be involved in mediating somatic withdrawal, whereas brain regions that loaded onto PC1 may be associated with other aspects of precipitated withdrawal.
withdrawal. Bodyweight loss, the PVN, VTA, and PAG did not load onto PC1 or PC2.

Correlations of c-Fos expression among brain regions following hyperalgesia during spontaneous heroin withdrawal

We used Pearson’s correlation tests to correlate the average number of c-Fos-expressing neurons among the analyzed brain regions for male and female heroin-treated mice (Fig. 5C). Among the brain regions that loaded with hyperalgesia in the same principal component, we found that the LH and VTA were the only brain regions that correlated with the LHB ($r = 0.67, p < 0.05$, and $r = 0.69, p < 0.05$, respectively), and the PBN only correlated with the DR ($r = 0.68, p < 0.05$). Across brain regions, we observed the strongest correlations of c-Fos expression between the LH and CeA ($r = 0.84, p < 0.001$), between the LH and VTA ($r = 0.86, p < 0.001$), between the LH and DR
Correlations of c-Fos expression among brain regions following naloxone-precipitated somatic signs of opioid withdrawal

Among the brain regions that loaded with somatic signs of opioid withdrawal in the same principal component, we found the strongest correlations of c-Fos expression between the PVT and LHb ($r = 0.91$, $p < 0.001$), between the DR and PVT ($r = 0.76$, $p < 0.01$), and between the DR and LC ($r = 0.76$, $p < 0.01$; Fig. 5D).

Discussion

In the present study, we found associations between c-Fos expression and two aspects of opioid withdrawal. We showed that the administration of escalating doses of heroin caused hyperalgesia during spontaneous withdrawal and somatic signs of withdrawal that was precipitated by naloxone in male and female mice. We used higher doses of heroin in the naloxone-precipitated withdrawal experiment to obtain robust signs of somatic withdrawal to model observations in people during early stages of opioid detoxification. We measured hyperalgesia 16 h after spontaneous withdrawal to minimize the potential effect of somatic withdrawal signs at earlier withdrawal timepoints on von Frey testing. The automatic cell detection and counting of c-Fos, a marker of neuronal activity, indicated that hyperalgesia and somatic withdrawal were associated with c-Fos expression in various brain regions. No sex × treatment interactions were found in behavioral responses or c-Fos expression. The neuronal activity of some of these regions uniquely correlated with either hyperalgesia or somatic withdrawal, whereas c-Fos expression in the DR and LC correlated with both behaviors (summary in Fig. 6). Based on these findings, we suggest that selected brain networks participate in the expression of different opioid withdrawal signs.

Although some studies identified sex differences in hyperalgesia during heroin withdrawal in rats (Marchette et al., 2021), we did not find sex differences in the present study in mice. In addition to species differences and specific timepoints of behavior assessment, the lack of sex differences in the present study may have resulted from the use of relatively high doses of heroin in both male and female mice (40–50 mg/kg twice daily). For somatic withdrawal, the lack of sex differences in our study is consistent with previous studies in rats and mice (Cicero et al., 2002; Towers et al., 2019). Both distinct and similar cellular and molecular mechanisms have been linked to hyperalgesia and somatic withdrawal (Maldonado et al., 1996; Largent-Milnes et al., 2008; Tsai et al., 2009; Corder et al., 2013; Brust et al., 2015). For example, $\kappa$-opioid receptor antagonist reversed hyperalgesia during spontaneous heroin withdrawal in male and female rats but did not affect somatic withdrawal (Marchette et al., 2021). However, antagonists of NMDA glutamate receptors, $\beta_2$-adrenergic receptors, serotonin 5-hydroxytryptamine-3 (5-HT3) receptors, and corticotropin-releasing factor 1 (CRF1) receptors attenuated both somatic withdrawal (Pinelli et al., 1997; Lu et al., 2000; Liang et al., 2007; Higgins et al., 2019) and hyperalgesia (Higgins et al., 1992; Liang et al., 2006, 2011; Harris et al., 2008; Park et al., 2015) in male rats and mice. These findings suggest both similarities and differences in the mechanisms that underlie hyperalgesia and somatic withdrawal.

We did not find sex × treatment interactions for c-Fos expression that was associated with hyperalgesia. For
somatic withdrawal, although we found a significant sex × treatment interaction for c-Fos levels in the SUM, the post hoc comparisons did not indicate meaningful sex differences. Therefore, we combined the male and female data for subsequent analyses. We observed significant correlations between hyperalgesia during spontaneous heroin withdrawal and c-Fos expression in the LH, CeA, VTA, DR, PBN, and LC. Previous studies reported increases in c-Fos expression in the CeA and LC during naloxone withdrawal–induced hyperalgesia in male and female oxycodone-dependent rats (Simpson et al., 2020). Consistent with the role of the CeA in mediating the neuropharmacological effect of heroin, an increase in BOLD activity was detected in amygdala nuclei during the presentation of cues that were associated with naloxone-induced heroin self-administration (Carmack et al., 2019). Additionally, pharmacological studies found that the intra-CeA administration of a CRF receptor antagonist reduced naloxone-precipitated hyperalgesia in male morphine-dependent rats (McNally and Akil, 2002). Studies that focused on the DR showed the local activation of microglia and astrocytes in male fentanyl-dependent rats, and the systemic administration of an anti-inflammatory agent prevented fentanyl withdrawal-induced hyperalgesia (Carranza-Aguilar et al., 2022). Another study demonstrated that μ-opioid receptor knock-out in the DR prevented the heroin withdrawal-induced reduction of social interaction in mice (Lutz et al., 2014).

We found a correlation between naloxone-precipitated somatic signs of withdrawal and c-Fos expression in some brain areas that were previously associated with opioid withdrawal, such as the DR, LC, LHb, and PVT. Studies of the LC found local increases in neuronal firing rate and upregulation of the cyclic adenosine monophosphate pathway during the expression of somatic signs of withdrawal in male rats (Rasmussen et al., 1990). Pharmacological studies of the LC also showed that intra-LC glutamate or norepinephrine neurotransmission blockers attenuated somatic signs of opioid withdrawal (Taylor et al., 1988, 1998). Neuronal circuitry studies established that excitatory projections from the PVT to the medial shell of the NAc are necessary for the mediation of somatic withdrawal in male mice (Zhu et al., 2016). Other brain areas where we detected a positive correlation of c-Fos expression were the LHb and DR, which have been previously implicated in morphine withdrawal (Valentinova et al., 2019).

Among the different brain areas that we analyzed, we found that c-Fos expression in the LC and DR correlated with both hyperalgesia during spontaneous withdrawal and somatic signs of naloxone-precipitated withdrawal. The LC is a primary noradrenergic nucleus that controls autonomic function and the stress response (Chandler, 2016). The DR contains the largest population of neurons that release serotonin in the forebrain and midbrain regions (Steinbusch, 1981). Studies of global alterations of the noradrenergic system by lesioning catecholamine neurons in the LC demonstrated that this global manipulation does not alter naloxone-induced conditioned place aversion, the expression of somatic withdrawal, or the attenuation of somatic withdrawal by the α2-adrenergic agonist clonidine (Britton et al., 1984; Caillé et al., 1999). In contrast to global manipulation of the noradrenergic system, the intra-LC administration of clonidine attenuated behavioral and neurochemical changes that were associated with naloxone-precipitated withdrawal (Taylor et al., 1988). Studies of the DR showed that the global lesion of serotoninergic neurons (Caillé et al., 2002) and μ-opioid receptor knock-out in the DR (Lutz et al., 2014) did not affect somatic signs of withdrawal. However, the systemic administration of a serotonin 5-HT2A receptor antagonist attenuated somatic signs of naloxone-precipitated heroin withdrawal (Bing et al., 2022). Other behavioral studies found that norepinephrine transmission and impairments in serotonergic signaling are associated with motivational and somatic withdrawal in opioid-dependent animals (Goeldner et al., 2011; Koob, 2021). Altogether, these findings suggest that the activation of specific types of neurons (via specific connectivity) in the LC and DR play distinct roles in different aspects of opioid withdrawal and highlight the complexity of brain network activity in mediating opioid withdrawal.

We found positive correlations among c-Fos levels in brain regions that are associated with hyperalgesia and somatic signs of withdrawal (see summary in Fig. 6). For c-Fos levels in brain regions that are associated with hyperalgesia, we detected a positive correlation between the LH and the CeA and VTA. Projections from the CeA to the LH mediate the avoidance of a stress-associated stimulus (i.e., a predictor of a poor response to substance use treatment; Weera et al., 2021). Moreover, a recent circuit-based study demonstrated that a LH projection to the VTA was associated with reward-omitted outcomes and defensive response to threatening stimuli (de Jong et al., 2019; Barbano et al., 2020). Positive correlations were also found between the DR and CeA. Projections from the DR to the CeA have been implicated in compulsive-like cocaine taking (Verheij et al., 2018). For c-Fos levels in brain regions that are associated with somatic withdrawal, we detected a positive correlation of c-Fos expression between the LHb and DR. Network connectivity studies reported that the inactivation of LHb glutamatergic projections to the DR reversed the reduction of sociability during morphine withdrawal in mice (Valentinova et al., 2019). Altogether, these results suggest a complex network of brain regions that could participate in the expression of hyperalgesia and somatic signs of opioid withdrawal.

We found no association between bodyweight loss during heroin treatment and hyperalgesia or somatic signs of withdrawal. This suggests that bodyweight loss is not a predictor for either of these two behavioral measures. Although we found an increase in c-Fos expression in the NAc shell, BNST, PVN, SUM, and PAG, none of these brain regions correlated with hyperalgesia during spontaneous withdrawal or somatic signs of naloxone-precipitated withdrawal. The activation of these brain regions may mediate motivational opioid withdrawal–related behaviors that were not evaluated in the present study (e.g.,
and anxiety-like behavior). Microinjections of a β-adrenergic receptor blocker and α2-adrenergic receptor agonist in the BNST (Delfs et al., 2000) and an AMPA receptor antagonist in the NAc shell (Russell et al., 2016) prevented naloxone-induced conditioned place aversion but had no effect on somatic withdrawal in male morphine-dependent rats. Studies of the NAc shell, BNST, PVN, SUM, and PAG may provide information about the roles of these brain regions in other opioid-related phenomena.

Clonidine and lofexidine, α2-adrenergic receptor agonists that suppress the adrenergic system, are used to treat somatic withdrawal symptoms during the acute phase of opioid withdrawal in humans, but they are ineffective for the long-term treatment of OUD (Gowing et al., 2009). Methadone and buprenorphine suppress both somatic and motivational symptoms and are used to treat OUD because they maintain opioid dependence. However, these medications have side-effects, and their discontinuation leads to withdrawal (Amato et al., 2004). Naltrexone decreases craving in people with OUD, but it is rarely prescribed because treatment initiation requires opioid abstinence, and poor adherence to treatment is an issue (Minozzi et al., 2011). The discovery of nonopioid neurotransmitter systems that mediate somatic and motivational symptoms of withdrawal could improve treatment outcomes for individuals with OUD. Thus, understanding common mechanisms that underlie somatic and motivational withdrawal could lead to new targets for drug development for OUD.

The present study has some limitations. We did not have groups of mice that received an acute injection of saline to make comparisons with the acute naloxone injection. However, the low c-Fos levels in chronically saline-treated mice compared with chronically heroin-treated mice following an acute injection of naloxone suggest that naloxone played a minimal role in c-Fos expression in nondependent mice. Although we did not design our experiments to directly compare c-Fos expression following the assessment of somatic withdrawal and hyperalgesia, c-Fos levels appeared to be lower in chronic saline-treated mice that received an acute naloxone injection than in chronic saline-treated mice that were tested for mechanical hyperalgesia. These results suggest that tactile stimulation of the hind paw with the rigid von Frey filament contributed to c-Fos expression in chronically saline-treated mice. Finally, we used passive injections of high heroin doses, so caution is needed when extrapolating our findings to lower doses or active drug intake.

In conclusion, hyperalgesia during spontaneous heroin withdrawal and somatic withdrawal were associated with the activity of different autonomic and limbic brain regions. Activity in the DR and LC, reflected by c-Fos expression, was associated with both behaviors in male and female mice. Future region-specific and cell type-specific studies will determine the functional involvement of different brain regions and neurotransmitter systems in negative emotional states (hyperkatifeia) that are associated with opioid withdrawal. Understanding alterations of neuronal activity and identifying potential neuronal networks that are associated with opioid withdrawal-related behaviors will also guide efforts to identify biomarkers of OUD and relapse.

References

Amato L, Davoli M, Ferri M, Gowing L, Perucci CA (2004) Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend 73:219–226.

Azar MR, Ahmed SH, Lintz R, Gutierrez T, Stinus L, Koob GF (2004) A non-invasive gating device for continuous drug delivery that allows control over the timing and duration of spontaneous opiate withdrawal. J Neurosci Methods 135:129–135.

Barbano MF, Wang HL, Zhang S, Miranda-Barrientos J, Estrin DJ, Figueroa-González A, Liu B, Barker DJ, Morales M (2020) VTA glutamatergic neurons mediate innate defensive behaviors. Neuron 107:368–382.e8.

Bing L, Jiang J, Zhou L, Tao X, Sun Q, Liu J, Liu Y, Pang G (2022) Blockade of 5-hydroxytryptamine 2A receptor attenuates precipitation of naloxone-induced withdrawal symptoms in opioid-exposed mice. Front Behav Neurosci 15:797217.

Borras MC, Becerra L, Ploeghaus A, Gostic JM, DaSilva A, Gonzalez RG, Borsook D (2004) FMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol 91:2723–2733.

Britton KT, Svensson T, Schwartz J, Bloom FE, Koob GF (1984) Dorsal noradrenergic bundle lesions fail to alter opiate withdrawal or suppression of opiate withdrawal by clonidine. Life Sci 34:133–139.

Brust TF, Conley JM, Watts VJ (2015) Gai/o-coupled receptor-mediated sensitization of adenyl cyclase: 40 years later. Eur J Pharmacol 763:223–232.

Caillé S, Espejo EF, Reneric JP, Cador M, Koob GF, Stinus L (1999) Total neurochemical lesion of noradrenergic neurons of the locus cœruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal. J Pharmacol Exp Ther 290:881–892.

Caillé S, Espejo EF, Koob GF, Stinus L (2002) Dorsal and median raphe serotoninergic system lesion does not alter the opiate withdrawal syndrome. Pharmacol Biochem Behav 72:979–986.

Carcoba LM, Contreras AE, Cepeda-Benito A, Meagher MW (2011) Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. J Addict Dis 30:258–270.

Carmack SA, Keeley RJ, Vendruscolo JCM, Lowery-Gionta EG, Lu H, Koob GF, Stein EA, Vendruscolo LF (2019) Heroin addiction engages negative emotional learning brain circuits in rats. J Clin Invest 129:2480–2484.

Carranza-Aguilar CJ, Hernández-Mendoza A, Mejías-Aponte C, Rice KC, Morales M, González-Espinosa C, Cruz SL (2022) Morphine and fentanyl repeated administration induces different levels of NLRP3-dependent pyroptosis in the dorsal raphe nucleus of male rats via cell-specific activation of TLR4 and opioid receptors. Cell Mol Neurobiol 42:677–694.

Chandler DJ (2016) Evidence for a specialized role of the locus coeruleus noradrenergic system in cortical circuitry and behavioral operations. Brain Res 1641:197–206.

Chu LF, Lin JC, Clemenson A, Encisco E, Sun J, Hoang D, Alva H, Erlandson M, Clark JD, Younger JW (2015) Acute opioid withdrawal is associated with increased neural activity in reward-processing centers in healthy men: a functional magnetic resonance imaging study. Drug Alcohol Depend 153:314–322.

Cicero TJ, Nock B, Meyer ER (2002) Gender-linked differences in the expression of physical dependence in the rat. Pharmacol Biochem Behav 72:691–697.

Corder G, Doolen S, Donahue RR, Winter MK, Jutras BL, He Y, Hu X, Wieskopf JS, Mogil JS, Storm DR, Wang ZJ, McCarson KE, Taylor BK (2013) Constitutive μ-opioid receptor activity leads to long-
term endogenous analgesia and dependence. Science 341:1394–1399.

de Jong JW, Afjei SA, Pollak Dorocic I, Peck JR, Liu C, Kim CK, Tian L, Deisseroth K, Lamme S (2019) A neural circuit mechanism for encoding aversive stimuli in the mesolimbic dopamine system. Neuron 101:133–151.e7.

Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000) Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced asersion. Nature 403:430–434.

Frenois F, Cador M, Caille S, Stinus L, Le Moine C (2002) Neural correlates of the motivational and somatic components of naloxone-prefixed morphine withdrawal. Eur J Neurosci 16:1377–1389.

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, national, and regional incidence, prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211–1259.

Goeldner C, Lutz PE, Darcq E, Halter T, Clesse D, Ouagazzal AM, Kieffer BL (2011) Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry 69:236–244.

Gowing L, Farrell M, Ali R, White JM (2009) Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev (2):CD002024.

Gracy KN, Dankiewicz LA, Koob GF (2001) Opiate withdrawal-induced Fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24:152–160.

Harris AC, Rothwell PE, Gewirtz JC (2008) Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia. Psychopharmacology (Berl) 196:649–660.

Higgins GA, Nguyen P, Sellers EM (1992) The NMDA antagonist dizocline (MK801) attenuates motivational as well as somatic aspects of naloxone-precipitated opioid withdrawal. Life Sci 50:PL167–PL172.

Higgins C, Smith BH, Matthews K (2019) Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth 122:e114–e126.

Konsman JP (2003) The mouse brain in stereotaxic coordinates. Psychoneuroendoecrinology 28:827–828.

Koob GF (2020) Neurobiology of opioid addiction: opponent process, hyperkatefia, and negative reinforcement. Biol Psychiatry 87:44–53.

Koob GF (2021) Drug addiction: hyperkatefia/negative reinforcement as a framework for medications development. Pharmacol Rev 73:163–201.

Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, Van Dyck CC, Price LH, George Zubal I, Hoffer PB, Charney DS (1995) Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse 21:47–63.

Largent-Miles TM, Guo W, Wang HY, Burns LH, Vanderw T (2008) Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated μ-opioid receptor-Gs coupling. J Pain 9:700–713.

Li Q, Wang Y, Zhang Y, Li W, Yang W, Zhu J, Wu N, Chang H, Zheng Y, Qin W, Zhao L, Yuan K, Liu J, Wang W, Tian J (2012) Craving correlates with mesolimbic responses to heroin-related cues in short-term abstinence from heroin: an event-related FMRI study. Brain Res 1468:63–72.

Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, David Clark J (2006) A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 104:1054–1062.

Liang DY, Shi X, Li X, Li J, Clark JD (2007) The B2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res 181:118–126.

Liang DY, Li X, Clark JD (2011) 5-Hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology 114:1180–1189.

Lowe AS, Williams SCR, Symms MR, Stolarman IP, Mohammed S (2002) Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal. Neuroimage 17:502–510.

Lu L, Liu D, Ceng X, Ma L (2000) Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12:4398–4404.

Lutz PE, Ayranzi G, Chush-Chung P, Matihas A, Koebel P, Fililoi D, Befort K, Ouagazzal AM, Kieffer BL (2014) Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence. Neuropsychopharmacology 39:2694–2705.

Maldonado R, Stinus L, Koob GF (1996) Neurobiological mechanisms of opiate withdrawal. Berlin: Springer.

Marchette RAN, Gregory-Flores A, Tunstall BJ, Carlson ER, Jackson SN, Sulima A, Rice KC, Koob GF, Vendrusco LF (2021) κ-Opioid receptor antagonism reverses heroin withdrawal-induced hyperalgesia in male and female rats. Neurobiol Stress 1:23:1168–1178.

National Institute on Drug Abuse (2022) Oversed death rates. National Institutes of Health. Accessed March 7, 2022. Available at https://nida.nih.gov/drug-topics/trends-statistics/overdose-death-rates.

Pantazis CB, Gonzalez LA, Tunstall BJ, Carmack SA, Koob GF, Vendrusco LF (2021) Cues conditioned to withdrawal and negative reinforcement: neglected but key motivational elements driving opioid addiction. Sci Adv 7:eabf0384.

Papaleo F, Contarino A (2006) Gender- and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice. Behav Brain Res 170:110–118.

Park PE, Schlosburg JE, Vendrusco LF, Schulteis G, Edwards S, Koob GF (2015) Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. Addict Biol 20:275–284.

Pinelli A, Trivulzio S, Tomasoni L (1997) Effects of ondansetron administration on opioid withdrawal syndrome observed in rats. Eur J Pharmacol 340:111–119.

Rasmussen K, Belfiner-Johnson DB, Krystal JH, Aghajanian GK, Nestler EJ (1990) Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci 10:2308–2317.

Russell SE, Puttick DJ, Sawyer AM, Potter DN, Mague S, Carlezon WA, Chartoff EH (2016) Nucleus accumbens AMPA receptors are necessary for morphine-withdrawal-induced negative-affective states in rats. J Neurosci 36:5748–5762.

Shurman J, Koob GF, Gutstein HB (2010) Opioids, pain, the brain, and hyperkatefia: a framework for the rational use of opioids for pain. Pain Med 11:1092–1098.

Simpson S, Kimbrough A, Boomhower B, McLeLLan R, Hughes M, Shankar K, de Guglielmo G, George O (2020) Depletion of the microbe alters the recruitment of neuronal ensembles of oxycodone intoxication and withdrawal. eNeuro 7:Eneuro.0312-19.2020.

Steinbusch HWM (1981) Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6:557–618.
Taylor JR, Elsworth JD, Garcia EJ, Grant SJ, Roth RH, Redmond DE (1988) Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology (Berl) 96:121–134.

Taylor JR, Punch LJ, Elsworth JD (1998) A comparison of the effects of clonidine and CNQX infusion into the locus coeruleus and the amygdala on naloxone-precipitated opiate withdrawal in the rat. Psychopharmacology (Berl) 138:133–142.

Towers EB, Tunstall BJ, McCracken ML, Vendruscolo LF, Koob GF (2019) Male and female mice develop escalation of heroin intake and dependence following extended access. Neuropharmacology 151:189–194.

Tsai RY, Tai YH, Tzeng Ji, Lin SL, Shen CH, Yang CP, Hsin ST, Wang CB, Wong CS (2009) Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the P38 mitogen-activated protein kinase signaling pathway. Neuroscience 159:1244–1256.

Valentinova K, Tchenio A, Trusel M, Clerke JA, Lalive AL, Tzanoulinou S, Matera A, Moutkine I, Maroteaux L, Paolicelli RC, Volterra A, Bellone C, Marmeli M (2019) Morphine withdrawal recruits lateral habenula cytokine signaling to reduce synaptic excitation and sociability. Nat Neurosci 22:1053–1056.

Verheij MMM, Contet C, Karel P, Latour J, van der Doelen RHA, Geenen B, van Hulten JA, Meyer F, Kozicz T, George O, Koob GF, Homberg JR (2018) Median and dorsal raphe serotonergic neurons control moderate versus compulsive cocaine intake. Biol Psychiatry 83:1024–1035.

Weera MM, Shackett RS, Kramer HM, Middleton JW, Gilpin NW (2021) Central amygdala projections to lateral hypothalamus mediate avoidance behavior in rats. J Neurosci 41:61–72.

Welsch L, Bailly J, Darcq E, Kieffer BL (2020) The negative affect of protracted opioid abstinence: progress and perspectives from rodent models. Biol Psychiatry 87:54–63.

Wooten GF, DiStefano P, Collins RC (1982) Regional cerebral glucose utilization during morphine withdrawal in the rat. Proc Natl Acad Sci U S A 79:3360–3364.

Zachry JE, Johnson AR, Calipari ES (2019) Sex differences in value-based decision making underlie substance use disorders in females. Alcohol Alcohol 54:339–341.

Zhu YC, Wienecke G, Nachtrab X Chen (2016) A thalamic input to the nucleus accumbens mediates opiate dependence. Nature 530:219–222.